You are here

Development of a lead cyclic-PDZ-Enhancer drug for Anxiety and Depression

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41MH118747-01A1
Agency Tracking Number: R41MH118747
Amount: $458,853.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 101
Solicitation Number: PA18-579
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-09-10
Award End Date (Contract End Date): 2021-07-31
Small Business Information
27 WALNUT RD, Barrington, RI, 02806-2028
DUNS: 080925349
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JOHN MARSHALL
 (401) 863-2574
 john_marshall@brown.edu
Business Contact
 JOHN MARSHALL
Phone: (401) 863-2574
Email: john_marshall@brown.edu
Research Institution
 BROWN UNIVERSITY
 350 EDDY STREET
PROVIDENCE, RI, 02912-9002
 Nonprofit college or university
Abstract
Major depressive disorder is a debilitating mood disorder that affectsof US adults in their lifetimecosting the U Seconomy more than $billion a yearDrugs that increase monoaminergic signaling are the mainstay of depression therapybut have a delayed onset of action and are only effective in aboutof affected patientsAberrant brain derived neurotrophic factorBDNFsignaling has been proposed to underlie the pathophysiology of major depressive disorder and Bipolar disorderWe have developed a novel family of cyclic peptidomimetic compounds that potentiate the BDNF pathways to produce rapidwithin hoursantidepressant effectsHerewe propose a Phase I proof ofconcept and feasibility study for the use of our patented new drugCNfor treating depressionThere are three major goals that focus on preclinical efficacyAimwill test the stability of CNanalogues and evaluate toxicityAimwill evaluate the rapid and long term effects of treatment with CNin mitigating depressive behaviors using two extensively validated modelsChronic mild stressCMSand Chronic social defeat stressCSDSAimwill examine the ability of CNto correct impairments in the cellular mechanisms of depression that include signalingneuronal atrophy and synaptic plasticity Major Depressive Disorder affects overmillion of the US population and represents a major cause of disability worldwideWe have engineered a unique drug exerting rapid therapeutic effects on depression pathwaysHerewe propose a Phase I proof of concept and feasibility study for the use of our patented new drugCNfor treating depressionResults of this study will point to novel therapeutic treatment for this devastating disorder

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government